What was the primary objective of the IMerge trial?
To evaluate the safety and tolerability of luspatercept in patients with low-risk MDS
To compare the efficacy of imetelstat versus placebo in achieving transfusion independence in MDS patients with a high burden of transfusion dependence
To assess the overall survival benefit of imetelstat in MDS patients with IPSS high risk